-
"Nature Cancer": Radiotherapy + immunity, better effect! Scientists have also discovered new prognostic markers
Time of Update: 2023-02-03
Pitroda from the Division of Radiation and Cell Oncology at the University of Chicago designed and conducted a investigator-initiated Phase 1/2, randomized clinical trial (COSINR study) evaluating the safety and efficacy of concurrent or sequential radiotherapy in combination with ICB (ipilimumab and nivolumab) as first-line treatment for metastatic non-small cell lung cancer (NSCLC).
-
Issues related to the rational use of nutritional preparations in patients with inflammatory bowel disease are clearly explained in one article
Time of Update: 2023-02-01
For medical professionals onlyContains 4 classic prescription analysis ~ written | Xie Dong and Tang Shihui inflammatory bowel disease (IBD), mainly including ulcerative colitis (UC) and Crohn disease
-
Use 3D modeling to stop the spread of cancer
Time of Update: 2022-11-04
Ioannis Zervantonakis, assistant professor of bioengineering at Pitt University, and his team received a four-year, $792,000 grant from the American Cancer Society to understand the biology behind the cellular interactions that lead to ovarian cancer metastasizing to other parts of the body.
-
Clopidogrel caused insulin autoimmune syndrome in 1 case
Time of Update: 2022-10-31
This article reports the diagnosis and treatment of a patient with acute coronary syndrome caused by clopidogrel IAS, in which IAA detection has differential diagnostic value for patients with hypoglycemia after myocardial infarction and is an important test index to evaluate the condition and efficacy.
-
J Clin Oncol: Cediranib in combination with olaparib for metastatic castration-resistant prostate cancer
Time of Update: 2022-10-25
In summary, Cediranib combined with olaparib significantly prolongs the radiographic progression-free survival of patients with metastatic castration-resistant prostate cancer compared with olaparib alone.
In summary, Cediranib combined with olaparib significantly prolongs the radiographic progression-free survival of patients with metastatic castration-resistant prostate cancer compared with olaparib alone.
-
Nutritional support for cancer patients: reasonable protein supplementation
Time of Update: 2022-09-08
Original title: Nutritional support for cancer patients: reasonable protein supplementationThe purpose of nutritional support treatment for cancer patients is to meet the nutritional needs of patients and improve their nutritional status; the second is to enhance the patient's immunity, improve the patient's tolerance to surgery, radiotherapy and chemotherapy, reduce the risk of recurrence, and improve the clinical outcome of patients , improve the quality of life .
-
Chest: The detection of PD-L1 expression in specimens obtained by bronchial ultrasound-guided needle aspiration (EBUS-TBNA) can also guide the application of PD1 inhibitors in patients with advanced
Time of Update: 2022-01-08
Therefore, a team from Canada has carried out related studies to evaluate whether the detection of PD-L1 expression in EBUS specimens and traditional tissue specimens can guide the efficacy of PD-1 inhibitors in the treatment of patients with advanced NSCLC .
-
Lepu Bio-PD-1 declared the second indication: MSI-H solid tumor
Time of Update: 2021-12-09
Author: ArmstrongOn October 26, 2021, the listing application of Lepu Bio's PD-1 monoclonal antibody Pritlizumab (HX008) for the treatment of MSI-H/dMMR solid tumors was accepted by NMPA, which is the second adaptation of the product declaration Disease .
-
[Science Sub-Journal] Cupping + new crown DNA vaccine = immune response × 100, Chinese scientists combined ancient and modern medicine, invented a new method of transfection
Time of Update: 2021-11-13
Researchers at Rutgers University studying COVID-19 used a suction technique similar to ancient cupping to invent a new method of delivering DNA molecules to skin cells .
-
Cancer Cell: Lung cancer fibroblasts influence the patient's response to treatment
Time of Update: 2021-11-02
expressionIn addition, this CAF functional classification is related to the patient's clinical response to targeted therapy and also to the tumor immune microenvironment , so it provides a way to guide personalized treatment .
-
Multiple research results of tislelizumab unveiled at ASCO 2021
Time of Update: 2021-06-23
On June 4, 2021, Beijing time, the annual event of the global oncology community-the American Society of Clinical Oncology (ASCO) annual meeting officially kicked off. BeiGene announced its solid tu
-
Lancet Sub-Journal | 1.3 million people data reminder: the second most common cancer, only this step, the outcome is very different
Time of Update: 2021-05-31
immunity The results showed that in countries with long-term colonoscopy and stool testing programs (such as Austria, the Czech Republic, and Germany), the incidence of CRC has dropped significantly over time, and the annual average percentage change (AAPC) of men has ranged from -2.
-
JCEM: The effect of behavioral intervention for weight loss and metformin on insulin-like growth factors in cancer survivors
Time of Update: 2021-05-08
Obese subjects still significantly reduced IGF-1 levels at 6 months (mean difference in change: -7.
1210/clinem/dgab266" target="_blank" rel="noopener">Effects of Behavioral Weight Loss and Metformin on Insulin-like Growth Factors in Cancer Survivors: A Randomized Trial .
-
The accuracy rate is nearly 90%, and Harvard's new AI system successfully assists in the diagnosis of skin cancer earlier
Time of Update: 2021-04-28
The new system successfully distinguished SPL from the non-suspicious lesions in the patient's skin photos, and included an "ugly duckling" standard for the first time, making its evaluation results 88% consistent with the consensus of the three dermatologists.
-
Professor Wang Dong: Progress in immunotherapy of advanced urothelial carcinoma
Time of Update: 2021-03-25
A summary of domestic and foreign first-line treatment related studies: Imvigor130 study IMVIGOR130 study is divided into three experimental groups: platinum-containing chemotherapy combined with atilizumab, chemotherapy combined with placebo, and atilizumab single agent, aiming to compare The efficacy and safety of each group of drugs in the first-line treatment of locally advanced or metastatic urothelial carcinoma.
